Recombinant Kunitz Protease Inhibitory Domain of the Amyloid β-Protein Precursor as an Anticoagulant in Venovenous Extracorporeal Circulation in Rabbits

Gail Annich; Tyler White; Deborah Damm; Yongqiang Zhao; Fahkri Mahdi; Jürgen Meinhardt; Sam Rebello; Benedict Lucchesi; Robert H. Bartlett; Alvin H. Schmaier

doi:10.1055/s-0037-1614858

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1999; 82(05): 1474-1481
DOI: 10.1055/s-0037-1614858

Rapid Communications

Schattauer GmbH

Recombinant Kunitz Protease Inhibitory Domain of the Amyloid β-Protein Precursor as an Anticoagulant in Venovenous Extracorporeal Circulation in Rabbits

Gail Annich

¹From the Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA

⁵Surgery, University of Michigan, Ann Arbor, MI, USA

,

Tyler White

²Scios, Inc. Sunnyvale, CA, USA

,

Deborah Damm

²Scios, Inc. Sunnyvale, CA, USA

,

Yongqiang Zhao

³Internal Medicine, University of Michigan, Ann Arbor, MI, USA

,

Fahkri Mahdi

³Internal Medicine, University of Michigan, Ann Arbor, MI, USA

,

Jürgen Meinhardt

⁵Surgery, University of Michigan, Ann Arbor, MI, USA

,

Sam Rebello

⁴Pharmacology, University of Michigan, Ann Arbor, MI, USA

,

Benedict Lucchesi

⁴Pharmacology, University of Michigan, Ann Arbor, MI, USA

,

Robert H. Bartlett

⁵Surgery, University of Michigan, Ann Arbor, MI, USA

,

Alvin H. Schmaier

³Internal Medicine, University of Michigan, Ann Arbor, MI, USA

› Institutsangaben

Abstract

Summary

Investigations were performed to characterize a recombinant Kunitz protease inhibitory domain of the amyloid β-protein precursor (rKPI) as anticoagulants. After a single intravenous infusion of wild type rKPI into dogs, its elimination fit a two compartment model with a t_½α and t_½β of 5 and 77 min, respectively. Further investigations determined if a variant form of rKPI with 178-fold more potent anti-factor Xa activity (rKPI-DD₁₃₅, K_i = 0.9 nM) could serve as an anticoagulant in a rabbit model of extracorporeal circulation using a venovenous shunt. A prospective investigation was initiated to compare standard heparin (n = 8) at 400 U/kg with different infusion concentrations of rKPI-DD₁₃₅. After a single intravenous infusion of 1.89 mg/kg of rKPI-DD₁₃₅followed by a constant infusion at 0.003 (n = 3), 0.03 (n = 7), or 0.3 (n = 5) mg/kg/min, the anti-factor Xa activity of the animals’ plasma rapidly reaches a steady state for the two lower infusion concentrations of the agent. All infusions of rKPI-DD₁₃₅ prolong the activated clotting time with less variation than that seen with heparin administration. rKPI-DD₁₃₅ anticoagulation does not prevent a drop in the platelet counts. Fibrinogen levels decrease only slightly when the circuit is anticoagulated with rKPI-DD₁₃₅. rKPI-DD₁₃₅ markedly prolongs the APTT, has little effect on the PT, and reduces plasma prekallikrein and plasminogen activation. The 0.3 mg/kg/min infusion concentration of rKPI-DD₁₃₅ results in reduced deposition of ¹¹¹Indium-labeled platelets on the circuit when compared to heparin. Last, after a steady state level is achieved, 60% of the plasma anti-factor Xa activity of rKPI-DD₁₃₅ is eliminated within 60 min after stopping the infusion. These data show the rKPI-DD₁₃₅ can provide single agent anticoagulation in a rabbit extracorporeal circuit. Development of short acting factor Xa inhibitors may be useful anticoagulants for cardiopulmonary bypass.

Abbreviations: CPB: cardiopulmonary bypass; KPI: Kunitz protease inhibitor domain; rKPI_WT: recombinant wild type Kunitz protease inhibitory domain of the amyloid β-protein precursor; rKPI-DD₁₃₅: recombinant Kunitz protease inhibitory domain of the amyloid β-protein which is a better inhibitor of factor Xa; ECC: extracorporeal circulation; CDP: citrate phosphate dextrose anti-coagulant; PRP: platelet-rich plasma; ACT: activated clotting time; PT: prothrombin time; APTT: activated partial thromboplastin time; PPP: platelet-poor plasma.

Key words

Amyloid β-protein precursor - factor Xa inhibitor - anticoagulant - ECC

Volltext

Referenzen

References
1 Trossaert M, Gaillard A, Commin PL, Amiral J, Vissac AM, Fressinaud E. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Brit J of Haemat 1998; 101: 653-5.
2 Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987; 2: 1289-91.
3 Van Nostrand WE, Wagner SL, Farrow JS, Cunningham DD. Immunopurification and protease inhibitory properties of protease nexin-2/amyloid beta-protein precursor. J Biol Chem 1990; 265: 9591-4.
4 Smith RP, Higuchi DA, Broze Jr GJ. Platelet coagulation factor XIa-inhibitor, a form of Alzheimer amyloid precursor protein. Science 1990; 248: 1126-8.
5 Schmaier AH, Dahl LD, Rozemuller AJM, Roos RAC, Wagner SL, Chung R, Van Nostrand WE. Protease nexin-2/amyloid β protein precursor. A tight-binding inhibitor of coagulation factor IXa. J Clin Invest 1993; 92: 2540-5.
6 Schmaier AH, Dahl LD, Hasan AAK, Cines DB, Bauer KA, Van Nostrand WE. Factor IXa inhibition by protease nexin-2/amyloid β-protein precursor on phospholipid vesicles and cell membranes. Biochemistry 1995; 34: 1171-8.
7 Mahdi F, Van Nostrand WE, Schmaier AH. Protease nexin-2/amyloid β-protein precursor inhibits factor Xa in the prothrombinase complex. J Biol Chem 1995; 270: 23468-74.
8 Van Nostrand WE, Schmaier AH, Farrow JS, Cunningham DD. Protease nexin-II (Amyloid β-protein precursor): A platelet α-granule protein. Science 1990; 248: 745-8.
9 Wagner SL, Siegel RS, Vedvick TS, Raschke WC, Van Nostrand WE. High level expression, purification, and characterization of the Kunitz-type protease inhibitor domain of protease nexin-2/amyloid beta-protein precursor. Biochem Biophys Res Comm 1992; 186: 1138-45.
10 Chase Jr T, Shaw E. p-Nitrophenyl-p’-guanidinobenzoate HCl: A new active site titrant for trypsin. Biochem Biophys Res Commun 1967; 29: 508-14.
11 Bieth JG. Theoretical and practical aspects of proteinase inhibition. Methods Enzymol 1995; 248: 59-84.
12 Bieth JG. In vivo significance of kinetic constants of protein proteinase inhibitors. Biochem Med 1984; 32: 387-97.
13 Rand ML, Packham MA, Mustard JF. Survival of density subpopulations of rabbit platelets: use of ⁵¹Cr- or ¹¹¹In-labeled platelets to measure survival of least dense and most dense platelets concurrently. Blood 1983; 61: 362-7.
14 Timmons S, Hawiger J. Separation of human platelets from plasma proteins including Factor VIII by a combined albumin gradient-gel filtration method using Hepes buffer. Thromb Res 1978; 12: 297-306.
15 Schmaier AH, Claypool W, Colman RW. Crotalocytin: recognition and purification of a timber rattlesnake platelet aggregating protein. Blood 1980; 56: 1013-9.
16 Rowland M, Tozer T. Clinical pharmacokinetics: concepts & applications. 2nd Edition. Lea & Febiger; Philadelphia, PA: 1989
17 DeLa Cadena R, Scott CF, Colman RW. Evaluation of a functional microassay for determination of plasma prekallikrein. J Lab Clin Med 1987; 109: 601-7.
18 Stassen JM, Lambeir AM, Matthyssens G, Ripka WC, Nystrom A, Sixma JJ, Vermylen J. Characterization of a novel series of aprotinin-derived anticoagulants. I. In vitro and pharmacological properties. Thromb Haemost 1995; 74: 646-54.
19 Harker LA, Hanson SR, Kelly AB. Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists. Thromb Haemost 1995; 74: 464-72.
20 Gitlin SD, Deeb GM, Yann C, Schmaier AH. Intraoperative monitoring of danaparoid sodium anticoagulation during cardiovascular operations. J Vasc Surg 1998; 27: 568-75.
21 Van Nostrand WE, Schmaier AH, Siegel RS, Wagner SL, Raschke WC. Enhanced plasmin inhibition by a reactive center lysine mutant of the Kunitz-type protease inhibitor domain of the amyloid b-protein precursor. J Biol Chem 1995; 270: 22827-30.